Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 21, 2016CSL Behring is proud to be a platinum sponsor of the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID) this week in Barcelona
21 Sep 2016 Hizentra® - the only 20% concentration SCIG with a proven track record of safety and efficacy for over 6 years; trusted by more than 18,000 patients and providers worldwide Privigen®...
-
Sep 16, 2016General Counsel Greg Boss of global biotherapeutics leader CSL Limited today accepted the World Recognition of Distinguished General Counsel from the Directors Roundtable in recognition of his professional accomplishments and passion for ethical leadership
16 Sep 2016 General Counsel Greg Boss of global biotherapeutics leader CSL Limited today accepted the World Recognition of Distinguished General Counsel from the Directors Roundtable in...
-
Sep 6, 2016CSL Behring is hosting an Expert Forum "Modifying Alpha-1 Antitrypsin Deficiency Related Emphysema" today during the 26th International Congress of the European Respiratory Society (ERS) in London.
06 Sep 2016 Global biotherapeutics leader CSL Behring will host an Expert Forum about Alpha-1 Antitrypsin Deficiency (AATD) today during the 26th International Congress of the European Respiratory...
-
Sep 2, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Release
-
Sep 1, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Aug 30, 2016The U.S. Food and Drug Administration (FDA) has accepted CSL Behring’s application for its low volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy for treating HAE. Upon FDA approval, CSL830 will be the first and only low volume, subcutaneous, prophylactic treatment option for HAE patients.
30 Aug 2016 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for its low-volume subcutaneous...
-
Aug 9, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Aug 4, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 27, 2016CSL Behring today presented data from a Phase III pivotal study of AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] in hemophilia A patients less than 12 years of age at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla.
27 Jul 2016 AFSTYLA prophylaxis and on-demand treatment demonstrated long-lasting hemostatic efficacy in pediatric patients with severe hemophilia A in phase III data presented Patients using AFSTYLA
-
Jul 26, 2016CSL Behring today announced new data from its Phase III PROLONG-9FP clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for treating hemophilia B.
26 Jul 2016 New analyses from global PROLONG-9FP clinical development program show: Adult patients prolonged dosing interval to up to 21 days for routine prophylaxis in extension study Mean...